Latest research
Latest corporate research
Latest tax enhanced reviews
Subscribe to our latest research
What we do
Investment research services
Tax enhanced research services
Bespoke consulting services
About
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact us
Our team
News & events
About Hardman & Co
Case studies
The team
News, podcasts & insights
Contact Us
Twitter icon
Created with Sketch.
×
Latest corporate investment research
Detailed company analysis created specifically for investors
Latest tax enhanced research
Product reports for investors and advisors
Latest published research
Services for corporates
Investment research & analysis
Detailed company analysis created specifically for investors
Services for private Companies
Tax enhanced research
Product reports for investors and advisors.
Bespoke consulting services
Bespoke services
Services for clients with specific needs
About
About Hardman & Co.
We are the longest-established commissioned research provider.
Insights
Group
Created with Sketch.
Podcasts
Group
Created with Sketch.
Videos
Group
Created with Sketch.
Events
Group
Created with Sketch.
See all news
Group
Created with Sketch.
Podcast
The EIS Navigator
Latest Episode
24: Making big ideas investible and measuring impact | Dan Somers of Boundary Capital
Stay up-to-date with the latest research
Sign up to our newsletter
COVID-19: -
Our Commitment to Client Service & Investor Communications
Life Sciences research
Shield Therapeutics Plc
Life Sciences
FDA approval ushers in a new era for Shield
By
Dr Dorothea Hill
02 Sep 2019
Advanced Oncotherapy
Life Sciences
Nearing the end-goal
By
Dr Martin Hall
08 Aug 2019
Stay up-to-date with the latest research
Sign up to our newsletter
Shield Therapeutics Plc
Life Sciences
FDA approval opens door to major US opportunity
By
Dr Dorothea Hill
05 Aug 2019
Redx Pharma
Life Sciences
Pan-RAF agreement strengthens balance sheet
By
Dr Gregoire Pave
18 Jul 2019
genedrive Plc
Life Sciences
Hepatitis C market frustrations
By
Dr Dorothea Hill
18 Jul 2019
Redx Pharma
Life Sciences
Phase I trial resumed
By
Dr Gregoire Pave
10 Jul 2019
Allergy Therapeutics plc
Life Sciences
Successful legal outcome removes uncertainty
By
Dr Dorothea Hill
01 Jul 2019
Oxford BioMedica
Life Sciences
Eying up long-term value
By
Dr Dorothea Hill
01 Jul 2019
Tissue Regenix
Life Sciences
Credit facilities expand cash runway to 2021
By
Dr Dorothea Hill
20 Jun 2019
Oxford BioMedica
Life Sciences
De-leveraging the balance sheet
By
Dr Dorothea Hill
18 Jun 2019
Allergy Therapeutics plc
Life Sciences
House dust mite vaccine – clinical progress
By
Dr Dorothea Hill
21 May 2019
Prev
1
...
3
4
5
6
7
...
17
Next
